|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
140,990,000 |
Market
Cap: |
73.88(M) |
Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
52
Week Range: |
$0.2971 - $1.74 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
3 |
End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Carey Robert |
Director |
|
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
7,500 |
|
- |
|
Meyers James R |
Director |
|
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
7,500 |
|
- |
|
Smith Karen L. |
Director |
|
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
10,000 |
|
- |
|
Parker H Stewart |
Director |
|
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
15,500 |
|
- |
|
Dilly Stephen George |
Director |
|
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
7,500 |
|
- |
|
Ramasastry Saira |
Director |
|
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
7,500 |
|
- |
|
Zakrzewski Joseph S |
Director |
|
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
32,500 |
|
- |
|
Duraibabu Prathyusha |
VP Principal Acct. Officer |
|
2020-04-25 |
4 |
D |
$8.32 |
$5,383 |
D/D |
(647) |
26,603 |
|
- |
|
Biogen Ma Inc. |
10% Owner |
|
2020-04-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
24,420,157 |
|
- |
|
Duraibabu Prathyusha |
VP Principal Acct. Officer |
|
2020-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
27,250 |
|
- |
|
Dilly Stephen George |
Director |
|
2020-03-19 |
4 |
AS |
$6.00 |
$210,000 |
D/D |
(35,000) |
5,000 |
|
- |
|
Dilly Stephen George |
Director |
|
2020-03-19 |
4 |
OE |
$5.42 |
$189,700 |
D/D |
35,000 |
40,000 |
|
- |
|
Parker H Stewart |
Director |
|
2020-03-18 |
4 |
B |
$5.20 |
$15,585 |
D/D |
3,000 |
13,000 |
2.39 |
- |
|
Zakrzewski Joseph S |
Director |
|
2020-03-17 |
4 |
B |
$4.99 |
$24,950 |
D/D |
5,000 |
30,000 |
2.39 |
- |
|
Dilly Stephen George |
Director |
|
2020-03-16 |
4 |
AS |
$6.02 |
$90,261 |
D/D |
(15,000) |
5,000 |
|
- |
|
Dilly Stephen George |
Director |
|
2020-03-16 |
4 |
OE |
$5.42 |
$81,300 |
D/D |
15,000 |
20,000 |
|
- |
|
Zakrzewski Joseph S |
Director |
|
2020-03-13 |
4 |
B |
$5.67 |
$28,350 |
D/D |
5,000 |
25,000 |
2.39 |
- |
|
Zakrzewski Joseph S |
Director |
|
2020-03-12 |
4 |
B |
$6.31 |
$94,650 |
D/D |
15,000 |
20,000 |
2.39 |
- |
|
Duraibabu Prathyusha |
VP Principal Acct. Officer |
|
2020-02-25 |
4/A |
A |
$0.00 |
$0 |
D/D |
16,500 |
24,250 |
|
- |
|
Loeb Gary |
EVP, General Counsel & Sec. |
|
2020-02-25 |
4/A |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
Woolfson Adrian |
EVP Research & Development |
|
2020-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
Ramelmeier Rolf Andrew |
EVP, Technical Operations |
|
2020-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
69,128 |
|
- |
|
Ramelmeier Rolf Andrew |
EVP, Technical Operations |
|
2020-02-25 |
4 |
D |
$6.80 |
$11,580 |
D/D |
(1,703) |
14,128 |
|
- |
|
Lee Sung |
EVP, Chief Financial Officer |
|
2020-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
93,750 |
|
- |
|
Boissel Stephane |
EVP, Corp. Strategy |
|
2020-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
70,116 |
|
- |
|
521 Records found
|
|
Page 8 of 21 |
|
|